TY - JOUR
T1 - Evaluating the causal effects of circulating metabolic biomarkers on Alzheimer's disease
AU - Du, Jianbin
AU - Baranova, Ancha
AU - Cao, Hongbao
AU - Zhang, Fuquan
N1 - Publisher Copyright:
© 2025
PY - 2025/4/2
Y1 - 2025/4/2
N2 - Background: The diagnosis and treatment of Alzheimer's disease (AD) is challenging due to the complexity of its pathogenesis. Although research suggests a link between circulating metabolites and AD, their causal relationship is not fully understood. Methods: Based on publicly available genome-wide association study data, we investigated the causative relationship between AD (7759 cases and 334,740 controls) and 233 traits describing circulating metabolites (136,016 participants) using a two-sample Mendelian randomization (MR) method. We adopted the inverse variance weighted approach as the priority and performed sensitivity analyses with MR-Egger intercept method and Cochran's Q test. Results: The overall causal effect of circulating metabolic traits on AD was significantly higher than the inverse effect (beta: 0.15 ± 0.42 vs. 0.04 ± 0.07; p < 0.05). A total of 72 circulating metabolic traits (odd ratio (OR): 1.16–2.48) had a significant positive causal effect on AD, while a total of 16 circulating metabolic traits with significant negative causal effects on AD were detected (OR: 0.38–0.88). AD had a significant positive causal effect (OR: 1.02–1.17) on 142 circulating metabolic traits and a negative causal effect (OR: 0.87–0.99) on 43 circulating metabolic traits. Circulating metabolites that have a bi-directional causative relationship with AD mainly include apolipoprotein B levels, total cholesterol levels, total triglycerides levels, and omega-6 fatty acids levels. Conclusion: The causative relationship between AD and the circulating metabolic traits is complex and bidirectional. Analyzing metabolites causally involved in the development of AD may provide clues for identifying preventive and therapeutic targets for this disorder.
AB - Background: The diagnosis and treatment of Alzheimer's disease (AD) is challenging due to the complexity of its pathogenesis. Although research suggests a link between circulating metabolites and AD, their causal relationship is not fully understood. Methods: Based on publicly available genome-wide association study data, we investigated the causative relationship between AD (7759 cases and 334,740 controls) and 233 traits describing circulating metabolites (136,016 participants) using a two-sample Mendelian randomization (MR) method. We adopted the inverse variance weighted approach as the priority and performed sensitivity analyses with MR-Egger intercept method and Cochran's Q test. Results: The overall causal effect of circulating metabolic traits on AD was significantly higher than the inverse effect (beta: 0.15 ± 0.42 vs. 0.04 ± 0.07; p < 0.05). A total of 72 circulating metabolic traits (odd ratio (OR): 1.16–2.48) had a significant positive causal effect on AD, while a total of 16 circulating metabolic traits with significant negative causal effects on AD were detected (OR: 0.38–0.88). AD had a significant positive causal effect (OR: 1.02–1.17) on 142 circulating metabolic traits and a negative causal effect (OR: 0.87–0.99) on 43 circulating metabolic traits. Circulating metabolites that have a bi-directional causative relationship with AD mainly include apolipoprotein B levels, total cholesterol levels, total triglycerides levels, and omega-6 fatty acids levels. Conclusion: The causative relationship between AD and the circulating metabolic traits is complex and bidirectional. Analyzing metabolites causally involved in the development of AD may provide clues for identifying preventive and therapeutic targets for this disorder.
KW - Alzheimer's disorder
KW - Ciculating metabolitic biomarks
KW - Mendelian randomization analysis
KW - Neurodegenerative diseases
KW - Psychiatry
UR - http://www.scopus.com/inward/record.url?scp=86000188262&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2025.111309
DO - 10.1016/j.pnpbp.2025.111309
M3 - Artículo
C2 - 40037511
AN - SCOPUS:86000188262
SN - 0278-5846
VL - 138
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
M1 - 111309
ER -